Ancon Technologies

A Message from Lord Pickles and Lord Blunkett, followed by Ancon Technologies's best practice article

The ability to listen and learn from one another has always been vital in parliament, in business and in most aspects of daily life. But at this particular moment in time, as national and global events continue to reiterate, it is uncommonly crucial that we forge new channels of communication and reinforce existing ones. The following article from Ancon Technologies is an attempt to do just that. We would welcome your thoughts on this or any other Parliamentary Review article.

Blunkett signature Rt Hon The Lord David Blunkett, MP
Pickles signature Rt Hon The Lord Eric Pickles, MP
35ANCON TECHNOLOGIES |
BEST PRACTICE REPRESENTATIVE 2018
Inventor Dr Gorbunov
Chemical and second-generation
explosive detection
Across the globe, the news broadcasts a seemingly endless
parade of emerging new threats that compromise
both safety and peace of mind. From terror attacks to
pandemic diseases, the world has never seemed more insecure,
challenged by hazards that look unrecognisable, unpredictable
or unstoppable. Whether the threat is from an explosive
device, a deadly disease or an illegal narcotic, early detection
has always been the first line of defence. Many of the current
systems designed to provide early warning rely on technology
that is decades old, with slow reaction times and high costs.
ANCON Technologies is now entering a period which will see its
developments in detection equipment for security and medical
applications change the market fundamentally.
An innovative early detection technology
Now, we are using the emerging field of nanotechnology to bring about a
fundamental transformation in the science supporting early warning sensors. The
Canterbury-based, privately owned company is developing breakthrough chemical
detection technology, a new level of detection that will disrupt the traditional
security industry marketplace.
Nanotechnology molecular tagging (NMT) offers the most sensitive detection of
trace chemicals in the atmosphere to date. The applications are broad reaching,
providing accurate detection of explosive materials, quick warning of radioactivity
and early diagnosis of disease infection.
FACTS ABOUT
ANCON TECHNOLOGIES
»CEO (UK): Dr Robert Muir
»Development director (UK)
and CEO (US): Wesley Baker
»Technical director:
DrBorisGorbunov
»Established in 2003
»Based in Canterbury, Kent,
and Bloomington, Minnesota
»Services: Medical, security
and aerosol technology
development
»No. of employees: 15
www.anconmedical.com
ANCON Technologies
THE PARLIAMENTARY REVIEW
Highlighting best practice
36 | ANCON TECHNOLOGIES
A timely solution to an urgent
chemical problem
As threats of chemical attack continue
to mount, government officials are
pushing for better security standards,
with regulations requiring upgraded
equipment in some transportation
systems and the implementation of
mass screening of venues.
The need for early detection methods
has never been more evident. The
chemical attack this year in Salisbury
showed the danger that chemicals
continue to pose to the public.
We offer a state-of-the-art security
device that can swiftly and reliably
detect the presence of explosives,
chemicals or other compounds
through precise atmospheric readings,
which are accurate down to the
molecular level. This advantage makes
our security products a thousand times
more sensitive than market leaders.
Disruptive breakthrough in
screening, diagnosis and
disease management
We have developed a “once-in-
a-generation technology” known
as nanoparticle biomarker tagging
(NBT). The mission is to bring this
technology to the medical screening
and diagnostic market. NBT will have
a similar impact in today’s healthcare
market as the MRI and x-ray created in
the past and will generate very-early-
stage screening and diagnosis via a
non-invasive breath test.
This technique uses biomarker disease
profiling and the latest artificial
intelligence software, so every patient
increases the knowledge stored in
the cloud database and the screening
process becomes ever more accurate.
Nanoparticle biomarker tagging:
non-invasive, quick and precise
NBT screening and diagnosis systems
will be in every medical clinic, hospital,
pharmacy and public health setting,
providing real-time early-stage
screening and diagnosis for cancers
and other diseases, leading to effective,
personalised treatments that will save
lives, improve quality of life and reduce
the cost of long-term medical care.
The NBT will also be used as a disease
management tool, monitoring the effects
of treatments such as chemotherapy
and radiotherapy in a live data setting.
Nanoparticle biomarker tagging is the
only technology that directly detects
concentration, through an inventive
process that tags and counts the
elemental unit of mass – the single
molecule through breath. This non-
invasive, versatile technology is truly at
the cutting edge of innovation in the
medical device industry.
How nanoparticle biomarker
tagging works
Nanoparticle biomarker tagging
can be utilised as the foundation of
a device that serves as a portable
micro-laboratory. The process is similar
to gas chromatography with mass
spectrometry detection; however, the
latter requires a high vacuum that
makes it expensive, slow and suitable
only for laboratory study. Conversely,
nanoparticle biomarker tagging
technology ionises a breath sample, tags
the ions with specially generated nano-
objects and then uses a laser to count
the molecules, to identify the biomarker
chemicals and to gauge concentrations.
The nano-objects serve to increase
the physical volume of each targeted
Non-invasive lung cancer
screening and diagnosis
Environmental
monitoring
Once-in-a-
generation
technology
37ANCON TECHNOLOGIES |
BEST PRACTICE REPRESENTATIVE 2018
molecule by more than one billion times,
making it visible to optical lasers for
counting. It is cheap and cost-effective
to operate.
Once the results are received via the
NBT, the device creates a specific
unique profile of the patient’s breath
and, using artificial machine learning
technology in the cloud, builds a matrix
for screening the patient. This is, in
effect, Star Trek technology. The patient
breathes into the device for one minute
and a result is provided in under ten
minutes for the medical professional.
This approach leads to many advantages,
including:
»Unprecedented sensitivities to be
able to screen and diagnose disease;
»Simplicity of use allowing for
professionals to be utilised elsewhere
while test is ongoing;
»Cheap and cost-effective to deliver;
»Non-invasive and quick allowing for
mass screening capability that is easy
to implement;
»Results generated in a short time
frame saving time and money for the
medical industry.
The result is a real-time, non-invasive
screening detection device that outpaces
current technology in many qualities,
including costs, sensitivity and portability.
Versatile applications, limitless
potential
With its advance research programme,
we are targeting our product
development towards the new
generation of detection devices.
For security providers, the technology
is programmed for accurate, sensitive
detection of trace elements of explosive
material, but it can be adapted to
detect radiation or illegal narcotics.
In the healthcare industry, the technology
provides a method for rapid early
screening and diagnosis of infectious
diseases like tuberculosis and influenza,
and also lung cancer, simply by
checking a subject’s breath for chemical
biomarkers that indicate the disease.
The same medical applications can also
be extended to veterinary medicine,
with further uses for petrochemical and
food safety functions also in the works.
The path to market
This is only our beginning; we
seek to build a revenue model on
manufacturing in the medical device
industry and licensing within the
security industry and supplying key
components to “prime” defence
and security suppliers. Furthermore,
we are looking to develop long-term
partnerships with numerous civil bodies
across the UK and the US including the
NHS and Homeland Security.
As threats continue to develop, so
must the means by which to combat
them, be this in explosives, chemicals
or weaponised disease. Without
fundamental improvements in
technology, many of these vulnerabilities
remain a threat every day to Britons and
citizens the world over. We are poised
to revolutionise both security detection
and medical diagnosis worldwide with
advanced products and technology that
stand to disrupt the current marketplace
while making the world a safer place.
Non-invasive
and quick
allowing for
mass
screening
Nanoparticle biomarker
tagging (NBT) is quick
and easy to use

The Parliamentary Review Publication, in which this article originally appeared, contained the following foreword from the prime minister.

The Rt Hon Theresa May MP's Foreword For The Parliamentary Review

By The Rt Hon Theresa May MP

British politics provides ample material for analysis in the pages of The Parliamentary Review. For Her Majesty’s Government, our task in the year ahead is clear: to achieve the best Brexit deal for Britain and to carry on our work to build a more prosperous and united country – one that truly works for everyone. 

The right Brexit deal will not be sufficient on its own to secure a more prosperous future for Britain. We also need to ensure that our economy is ready for what tomorrow will bring. Our Modern Industrial Strategy is our plan to do that. It means Government stepping up to secure the foundations of our productivity: providing an education system that delivers the skills our economy needs, improving school standards and transforming technical education; delivering infrastructure for growth; ensuring people have the homes they need in the places they want to live. It is all about taking action for the long-term that will pay dividends in the future.

But it also goes beyond that. Government, the private sector and academia working together as strategic partners achieve far more than we could separately. That is why we have set an ambitious goal of lifting UK public and private research and development investment to 2.4 per cent of GDP by 2027. It is why we are developing four Grand Challenges, the big drivers of social and economic change in the world today: harnessing artificial intelligence and the data revolution; leading in changes to the future of mobility; meeting the challenges of our ageing society; and driving ahead the revolution in clean growth. By focusing our efforts on making the most of these areas of enormous potential, we can develop new exports, grow new industries and create more good jobs in every part of our country.

Years of hard work and sacrifice from the British people have got our deficit down by over three quarters. We are building on this success by taking a balanced approach to public spending. We are continuing to deal with our debts, so that our economy can remain strong and we can protect people’s jobs, and at the same time we are investing in vital public services, like our NHS. We have set out plans to increase NHS funding annually by an average by 3.4 percent in real terms: that is £394 million a week more. In return, the NHS will produce a ten-year plan, led by doctors and nurses, to eliminate waste and improve patient care.

I believe that Britain can look to the future with confidence. We are leaving the EU and setting a new course for prosperity as a global trading nation. We have a Modern Industrial Strategy that is strengthening the foundations of our economy and helping us to seize the opportunities of the future. We are investing in the public services we all rely on and helping them to grow and improve. Building on our country’s great strengths – our world-class universities and researchers, our excellent services sector, our cutting edge manufacturers, our vibrant creative industries, our dedicated public servants – we can look towards a new decade that is ripe with possibility. The government I lead is doing all it can to make that brighter future a reality for everyone in our country. 

British politics provides ample material for analysis in the pages of The Parliamentary Review 
The Rt Hon Theresa May MP
Prime Minister